B-Organism_substance	0	5	Serum	Serum	NN	B-NP
O	6	13	soluble	soluble	JJ	I-NP
O	14	22	vascular	vascular	JJ	I-NP
O	23	31	adhesion	adhesion	NN	I-NP
O	32	39	protein	protein	NN	I-NP
O	39	40	-	-	HYPH	B-NP
O	40	41	1	1	CD	I-NP
O	42	44	is	be	VBZ	B-VP
O	45	46	a	a	DT	B-NP
O	47	55	valuable	valuable	JJ	I-NP
O	56	66	prognostic	prognostic	JJ	I-NP
O	67	73	marker	marker	NN	I-NP
O	74	76	in	in	IN	B-PP
B-Cancer	77	84	gastric	gastric	JJ	B-NP
I-Cancer	85	91	cancer	cancer	NN	I-NP
O	91	92	.	.	.	O

O	94	104	BACKGROUND	BACKGROUND	NN	B-NP
O	104	105	:	:	:	O
O	106	114	Vascular	Vascular	JJ	B-NP
O	115	123	adhesion	adhesion	NN	I-NP
O	124	131	protein	protein	NN	I-NP
O	131	132	-	-	HYPH	B-NP
O	132	133	1	1	CD	I-NP
O	134	135	(	(	(	O
O	135	138	VAP	VAP	NN	B-NP
O	138	139	-	-	HYPH	B-NP
O	139	140	1	1	CD	I-NP
O	140	141	)	)	)	O
O	142	151	regulates	regulate	VBZ	B-VP
B-Cell	152	161	leukocyte	leukocyte	NN	B-NP
I-Cell	162	168	tissue	tissue	NN	I-NP
O	169	181	infiltration	infiltration	NN	I-NP
O	181	182	.	.	.	O

O	183	191	Elevated	Elevated	JJ	B-NP
B-Organism_substance	192	197	serum	serum	NN	I-NP
O	198	205	soluble	soluble	JJ	I-NP
O	206	209	VAP	VAP	NN	I-NP
O	209	210	-	-	HYPH	B-NP
O	210	211	1	1	CD	I-NP
O	212	213	(	(	(	O
O	213	217	sVAP	sVAP	NN	B-NP
O	217	218	-	-	HYPH	B-NP
O	218	219	1	1	CD	I-NP
O	219	220	)	)	)	O
O	221	227	levels	level	NNS	B-NP
O	228	233	occur	occur	VBP	B-VP
O	234	236	in	in	IN	B-PP
O	237	244	certain	certain	JJ	B-NP
O	245	253	diseases	disease	NNS	I-NP
O	254	260	having	have	VBG	B-VP
O	261	263	an	an	DT	B-NP
O	264	276	inflammatory	inflammatory	JJ	I-NP
O	277	286	component	component	NN	I-NP
O	286	287	.	.	.	O

O	288	290	We	We	PRP	B-NP
O	291	301	previously	previously	RB	B-ADVP
O	302	308	showed	show	VBD	B-VP
O	309	311	in	in	IN	B-PP
B-Cancer	312	322	colorectal	colorectal	JJ	B-NP
I-Cancer	323	329	cancer	cancer	NN	I-NP
O	330	334	that	that	IN	B-SBAR
O	335	339	sVAP	sVAP	NN	B-NP
O	339	340	-	-	HYPH	B-NP
O	340	341	1	1	CD	I-NP
O	342	352	expression	expression	NN	I-NP
O	353	355	is	be	VBZ	B-VP
O	356	369	significantly	significantly	RB	B-ADJP
O	370	376	higher	high	JJR	I-ADJP
O	377	385	relative	relative	JJ	B-ADVP
O	386	388	to	to	TO	B-PP
O	389	397	controls	control	NNS	B-NP
O	397	398	,	,	,	O
O	399	402	and	and	CC	O
O	403	407	this	this	DT	B-NP
O	408	417	decreased	decrease	VBN	I-NP
O	418	428	expression	expression	NN	I-NP
O	429	431	is	be	VBZ	B-VP
O	432	442	associated	associate	VBN	I-VP
O	443	447	with	with	IN	B-PP
O	448	452	poor	poor	JJ	B-NP
O	453	462	prognosis	prognosis	NN	I-NP
O	463	466	and	and	CC	I-NP
B-Multi-tissue_structure	467	472	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	473	477	node	node	NN	I-NP
O	478	481	and	and	CC	O
B-Organ	482	487	liver	liver	NN	B-NP
O	488	498	metastasis	metastasis	NN	I-NP
O	498	499	.	.	.	O

O	500	507	However	However	RB	B-ADVP
O	507	508	,	,	,	O
O	509	513	sVAP	sVAP	NN	B-NP
O	513	514	-	-	HYPH	O
O	514	515	1	1	CD	B-NP
O	516	526	expression	expression	NN	I-NP
O	527	530	has	have	VBZ	B-VP
O	531	534	not	not	RB	I-VP
O	535	539	been	be	VBN	I-VP
O	540	549	described	describe	VBN	I-VP
O	550	553	for	for	IN	B-PP
B-Cancer	554	561	gastric	gastric	JJ	B-NP
I-Cancer	562	568	cancer	cancer	NN	I-NP
O	568	569	.	.	.	O

O	570	574	This	This	DT	B-NP
O	575	580	study	study	NN	I-NP
O	581	591	determines	determine	VBZ	B-VP
O	592	595	the	the	DT	B-NP
O	596	608	relationship	relationship	NN	I-NP
O	609	616	between	between	IN	B-PP
O	617	629	preoperative	preoperative	JJ	B-NP
B-Organism_substance	630	635	serum	serum	NN	I-NP
O	636	640	sVAP	sVAP	NN	I-NP
O	640	641	-	-	HYPH	B-NP
O	641	642	1	1	CD	I-NP
O	643	649	levels	level	NNS	I-NP
O	650	653	and	and	CC	O
O	654	673	clinicopathological	clinicopathological	JJ	B-NP
O	674	682	features	feature	NNS	I-NP
O	683	686	and	and	CC	O
O	687	696	prognosis	prognosis	NN	B-NP
O	697	699	in	in	IN	B-PP
B-Cancer	700	707	gastric	gastric	JJ	B-NP
I-Cancer	708	714	cancer	cancer	NN	I-NP
O	714	715	.	.	.	O

O	716	723	METHODS	METHODS	NNS	B-NP
O	723	724	:	:	:	O
O	725	737	Preoperative	Preoperative	JJ	B-NP
B-Organism_substance	738	743	serum	serum	NN	I-NP
O	744	747	was	be	VBD	B-VP
O	748	757	collected	collect	VBN	I-VP
O	758	762	from	from	IN	B-PP
O	763	766	107	107	CD	B-NP
B-Cancer	767	774	gastric	gastric	JJ	I-NP
I-Cancer	775	781	cancer	cancer	NN	I-NP
O	782	790	patients	patient	NNS	I-NP
O	791	794	and	and	CC	O
O	795	797	33	33	CD	B-NP
O	798	804	normal	normal	JJ	I-NP
O	805	813	controls	control	NNS	I-NP
O	813	814	.	.	.	O

O	815	819	sVAP	sVAP	NN	B-NP
O	819	820	-	-	HYPH	B-NP
O	820	821	1	1	CD	I-NP
O	822	828	levels	level	NNS	I-NP
O	829	833	were	be	VBD	B-VP
O	834	841	assayed	assay	VBN	I-VP
O	842	844	by	by	IN	B-PP
O	845	851	enzyme	enzyme	NN	B-NP
O	851	852	-	-	HYPH	O
O	852	858	linked	link	VBN	B-VP
O	859	872	immunosorbent	immunosorbent	JJ	B-NP
O	873	878	assay	assay	NN	I-NP
O	878	879	.	.	.	O

O	880	887	RESULTS	RESULTS	NNS	B-NP
O	887	888	:	:	:	O
O	889	892	The	The	DT	B-NP
O	893	897	mean	mean	JJ	I-NP
O	898	902	sVAP	sVAP	NN	I-NP
O	902	903	-	-	HYPH	I-NP
O	903	904	1	1	CD	I-NP
O	905	910	level	level	NN	I-NP
O	911	914	for	for	IN	B-PP
B-Cancer	915	921	cancer	cancer	NN	B-NP
O	922	930	patients	patient	NNS	I-NP
O	931	934	was	be	VBD	B-VP
O	935	948	significantly	significantly	RB	B-ADJP
O	949	955	higher	high	JJR	I-ADJP
O	956	964	relative	relative	JJ	B-ADVP
O	965	967	to	to	TO	B-PP
O	968	976	controls	control	NNS	B-NP
O	976	977	,	,	,	O
O	978	981	and	and	CC	O
O	982	991	decreased	decrease	VBD	B-VP
O	992	996	with	with	IN	B-PP
O	997	1004	disease	disease	NN	B-NP
O	1005	1016	progression	progression	NN	I-NP
O	1016	1017	.	.	.	O

B-Cancer	1018	1023	Tumor	Tumor	NN	B-NP
O	1024	1028	size	size	NN	I-NP
O	1028	1029	,	,	,	O
B-Multi-tissue_structure	1030	1037	serosal	serosal	JJ	B-NP
O	1038	1046	invasion	invasion	NN	I-NP
O	1046	1047	,	,	,	O
B-Multi-tissue_structure	1048	1053	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1054	1058	node	node	NN	I-NP
O	1059	1069	metastasis	metastasis	NN	I-NP
O	1069	1070	,	,	,	O
B-Multi-tissue_structure	1071	1081	peritoneal	peritoneal	JJ	B-NP
O	1082	1095	dissemination	dissemination	NN	I-NP
O	1095	1096	,	,	,	O
O	1097	1100	and	and	CC	O
O	1101	1104	TNM	TNM	NN	B-NP
O	1105	1119	classification	classification	NN	I-NP
O	1120	1123	was	be	VBD	B-VP
O	1124	1137	significantly	significantly	RB	I-VP
O	1138	1148	correlated	correlate	VBN	I-VP
O	1149	1153	with	with	IN	B-PP
O	1154	1158	sVAP	sVAP	NN	B-NP
O	1158	1159	-	-	HYPH	I-NP
O	1159	1160	1	1	CD	I-NP
O	1161	1166	level	level	NN	I-NP
O	1166	1167	.	.	.	O

O	1168	1172	sVAP	sVAP	NN	B-NP
O	1172	1173	-	-	HYPH	B-NP
O	1173	1174	1	1	CD	I-NP
O	1175	1177	is	be	VBZ	B-VP
O	1178	1182	also	also	RB	B-ADVP
O	1183	1185	an	an	DT	B-NP
O	1186	1197	independent	independent	JJ	I-NP
O	1198	1208	predictive	predictive	JJ	I-NP
O	1209	1215	marker	marker	NN	I-NP
O	1216	1219	for	for	IN	B-PP
B-Multi-tissue_structure	1220	1225	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1226	1230	node	node	NN	I-NP
O	1231	1241	metastasis	metastasis	NN	I-NP
O	1241	1242	.	.	.	O

O	1243	1251	Patients	Patient	NNS	B-NP
O	1252	1258	having	have	VBG	B-VP
O	1259	1262	low	low	JJ	B-NP
O	1263	1267	sVAP	sVAP	NN	I-NP
O	1267	1268	-	-	HYPH	B-NP
O	1268	1269	1	1	CD	I-NP
O	1270	1276	levels	level	NNS	I-NP
O	1277	1280	had	have	VBD	B-VP
O	1281	1294	significantly	significantly	RB	B-NP
O	1295	1301	poorer	poor	JJR	I-NP
O	1302	1311	prognosis	prognosis	NN	I-NP
O	1312	1320	relative	relative	JJ	B-ADVP
O	1321	1323	to	to	TO	B-PP
O	1324	1332	patients	patient	NNS	B-NP
O	1333	1339	having	have	VBG	B-VP
O	1340	1348	elevated	elevate	VBN	B-NP
O	1349	1353	sVAP	sVAP	NN	I-NP
O	1353	1354	-	-	HYPH	B-NP
O	1354	1355	1	1	CD	I-NP
O	1356	1358	in	in	IN	B-PP
O	1359	1362	all	all	DT	B-NP
O	1363	1365	or	or	CC	I-NP
O	1366	1372	stages	stage	NNS	I-NP
O	1373	1374	I	I	CD	I-NP
O	1374	1375	-	-	HYPH	I-NP
O	1375	1378	III	III	CD	I-NP
B-Cancer	1379	1386	gastric	gastric	JJ	I-NP
I-Cancer	1387	1393	cancer	cancer	NN	I-NP
O	1394	1402	patients	patient	NNS	I-NP
O	1402	1403	,	,	,	O
O	1404	1416	respectively	respectively	RB	B-ADVP
O	1416	1417	.	.	.	O

O	1418	1429	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1429	1430	:	:	:	O
O	1431	1434	Low	Low	JJ	B-NP
O	1435	1439	sVAP	sVAP	NN	I-NP
O	1439	1440	-	-	HYPH	B-NP
O	1440	1441	1	1	CD	I-NP
O	1442	1448	levels	level	NNS	I-NP
O	1449	1452	are	be	VBP	B-VP
O	1453	1463	associated	associate	VBN	I-VP
O	1464	1468	with	with	IN	B-PP
O	1469	1473	poor	poor	JJ	B-NP
O	1474	1483	prognosis	prognosis	NN	I-NP
O	1484	1486	in	in	IN	B-PP
B-Cancer	1487	1494	gastric	gastric	JJ	B-NP
I-Cancer	1495	1501	cancer	cancer	NN	I-NP
O	1501	1502	.	.	.	O

O	1503	1514	Determining	Determine	VBG	B-VP
O	1515	1519	sVAP	sVAP	NN	B-NP
O	1519	1520	-	-	HYPH	O
O	1520	1521	1	1	CD	B-NP
O	1522	1528	levels	level	NNS	I-NP
O	1529	1532	may	may	MD	B-VP
O	1533	1535	be	be	VB	I-VP
O	1536	1544	valuable	valuable	JJ	B-ADJP
O	1545	1548	for	for	IN	B-PP
O	1549	1559	predicting	predict	VBG	B-VP
O	1560	1569	prognosis	prognosis	NN	B-NP
O	1570	1573	and	and	CC	I-NP
B-Multi-tissue_structure	1574	1579	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	1580	1584	node	node	NN	I-NP
O	1585	1595	metastasis	metastasis	NN	I-NP
O	1595	1596	.	.	.	O

